Halifax Convention Centre

James Satterwhite, CEO of Advanced Glazings, Ltd., to Speak at BuildGreen Atlantic 2024 Conference

Retrieved on: 
Wednesday, March 13, 2024
NOVA, ASHRAE, Student, ICI, Halifax Convention Centre

BuildGreen Atlantic , Presented by Ashrae Halifax Chapter, is a conference, tradeshow and networking event that advances the design, construction, and operation of greener buildings in Atlantic Canada, and will be held in Halifax on March 26 & 27, 2024.

Key Points: 
  • BuildGreen Atlantic , Presented by Ashrae Halifax Chapter, is a conference, tradeshow and networking event that advances the design, construction, and operation of greener buildings in Atlantic Canada, and will be held in Halifax on March 26 & 27, 2024.
  • The 27th focuses on the conference and tradeshow at the Halifax Convention Centre.
  • Both days will attract the green building sector, including building owners, architects, engineers, designers, materials manufacturers, trade professionals, policymakers, and students.
  • James Satterwhite’s presentation promises to inspire architects, builders, and sustainability enthusiasts alike, to “Win the War on Dull Buildings.”

Winners Announced for the 2024 JUNO Opening Night Awards Presented by Music Canada

Retrieved on: 
Sunday, March 24, 2024
Instrumental, Juno Award, CARAS, GO, Single, Long, JUNO, Walt Grealis, Radio, Songwriter, Artist, SOCAN, Music Canada, Sirius XM Canada, WINNERS, NS, Halifax Convention Centre, Music

Special honours presented to Chip Sutherland (Walt Grealis Special Achievement Award) and performances from Aqyila, Begonia, Jah'Mila, Lili-Ann De Francesco and LU KALA.

Key Points: 
  • Special honours presented to Chip Sutherland (Walt Grealis Special Achievement Award) and performances from Aqyila, Begonia, Jah'Mila, Lili-Ann De Francesco and LU KALA.
  • HALIFAX, NS, March 23, 2024 /CNW/ - The Canadian Academy of Recording Arts and Sciences (CARAS) celebrated the artists and industry veterans at the top of Canada's music scene this evening at the 2024 JUNO Opening Night Awards Presented by Music Canada, at the Halifax Convention Centre.
  • The industry event was co-hosted by Aba Amuquandoh and Damhnait Doyle, featuring the presentation of 40+ JUNO Awards including Chip Sutherland receiving the Walt Grealis Special Achievement Award.
  • FOR A COMPLETE LIST OF WINNERS AT THE 2024 JUNO OPENING NIGHT AWARDS, GO TO WWW.JUNOAWARDS.CA .

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

Retrieved on: 
Wednesday, October 12, 2022
Gene expression, LinkedIn, U.S. Securities and Exchange Commission, GSK, Orphan, Fulcrum, Therapy, Ascending limb of loop of Henle, Sickle cell disease, Fetal hemoglobin, Review, Quality, Open-label trial, Thalassemia, WMS, Neuro, Muscle weakness, Facial expression, Patient, Facioscapulohumeral muscular dystrophy, Halifax Convention Centre, DUX4, OLE, Clinical trial, MFI, Twitter, HIV disease progression rates, Security (finance), Collection, Nasdaq, Private Securities Litigation Reform Act, Hemoglobinopathy, Șaeș, PGIC, Quality of life, Fast track (FDA), Muscular dystrophy, REACH, Safety, EDT, GLOBE, RWS, MAPK, FDA, COVID-19, Pharmaceutical industry, FSHD, Industry, Losmapimod

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that new data from the open label extension (OLE) portion of the Phase 2 ReDUX4 study of losmapimod for the treatment of FSHD will be featured in a poster presentation at the World Muscle Society (WMS) Hybrid Congress taking place October 11-15 in Halifax, Canada. Fulcrum will also host a symposium entitled “Measuring Progression in FSHD: Implications for Clinical Trials,” featuring an overview of the OLE data on October 12, 2022, at the Halifax Convention Center.

Key Points: 
  • ReDUX4 was a 48-week, placebo-controlled study that enrolled 80 participants between the ages of 18-65 with genetically confirmed FSHD1 (Ricci score 2-4).
  • Of the 77 participants who completed the initial 48-week study, 99% (n=76) enrolled in the OLE.
  • Data from the OLE support findings that losmapimod modifies FSHD disease progression and preserves or improves muscle function.
  • Following the completion of the trial, 99% of eligible participants elected to continue in the Open Label Extension trial.

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society

Retrieved on: 
Thursday, October 6, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Copenhagen, LinkedIn, Congress, Physical medicine and rehabilitation, Therapy, BMD, WMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Halifax Convention Centre, LYNX, University of Florida, Twitter, Professor, University of California, Davis, Rigshospitalet, Children's National Hospital, Nasdaq, University, DMD, Food, Biomarker, Rehabilitation, Company, ADT, Department, Pharmacokinetics, NSAA, Adult, Safety, Neuromuscular Disorders, Protein, Fast Track, Disability, PK, Myopathy, Edgewise, FDA, Pharmaceutical industry, Pharmacology, Facebook, Dystrophinopathy, Neurology

The conference will take place at the Halifax Convention Centre in Halifax, Nova Scotia, from October 11-15, 2022.

Key Points: 
  • The conference will take place at the Halifax Convention Centre in Halifax, Nova Scotia, from October 11-15, 2022.
  • The symposium will be streamed to the virtual element of the event and available for replay via the conference platform.
  • The Edgewise symposium presentation and posters will be available on the Edgewise website when they are presented.
  • EDG-5506 is an orally administered small molecule designed to address muscle damage induced by mechanical stress in dystrophinopathies including DMD and BMD.

Government of Canada to assist Nova Scotia with COVID-19 immunization program

Retrieved on: 
Tuesday, January 11, 2022
IWK Health Centre, Vaccine, Vaccination, National security, Executive Schedule, Intention, Surge (drink), Emergency, Government, The Honourable, Public Health Agency of Canada, Government of Canada, Red, COVID-19, Safety, Moderna, Health Canada, Queen, Canadian Forces National Investigation Service, Government of Nova Scotia, Department, Health, Time, International Red Cross and Red Crescent Movement, Privy council, Public Health Agency, Queen's Privy Council for Canada, Halifax Convention Centre, Department of National Defence (Canada), Workforce, Federation, Canadian Red Cross, Partnership, Animal, Pharmaceutical industry

The Red Cross deployment is funded by Public Safety's Humanitarian Workforce Program, which was established in Summer 2021, following the 2020 Fall Economic Statement.

Key Points: 
  • The Red Cross deployment is funded by Public Safety's Humanitarian Workforce Program, which was established in Summer 2021, following the 2020 Fall Economic Statement.
  • The Government Operations Centre is working closely with federal and provincial partners to coordinate the federal response to the situation in Nova Scotia.
  • The Government Operations Centre is responsible for coordinating the Government of Canada's response to emergency events including the pandemic.
  • It supports the Public Health Agency of Canada, which is the federal government lead for the response to COVID-19.

Halifax International Airport Authority and Destination Canada Sign Partnership Agreement

Retrieved on: 
Tuesday, May 15, 2018
Geography of Canada, Eastern Canada, Geography of Nova Scotia, Halifax International Airport Authority, Halifax, Nova Scotia, HIAA, NOVA SCOTIA, Halifax Convention Centre

HALIFAX, May 15, 2018 /CNW/ -Today, Halifax International Airport Authority (HIAA) and Destination Canada signed a marketing partnership agreement during the annual Rendez-vous Canada travel trade show, being held this week at the new Halifax Convention Centre in Halifax, Nova Scotia.

Key Points: 
  • HALIFAX, May 15, 2018 /CNW/ -Today, Halifax International Airport Authority (HIAA) and Destination Canada signed a marketing partnership agreement during the annual Rendez-vous Canada travel trade show, being held this week at the new Halifax Convention Centre in Halifax, Nova Scotia.
  • "This agreement will help us capitalize on the record-breaking growth we are seeing from France," said David F. Goldstein, President & CEO, Destination Canada.
  • Rendez-vous Canada is Canada's signature international tourism marketplace where the international travel trade connect with Canada's tourism industry partners.
  • Destination Canada markets Canada internationally as a premier four-season tourism destination.